

# Global Oncology Drugs Market 2018-2024

<https://marketpublishers.com/r/GC80C84A0B7EN.html>

Date: March 2018

Pages: 102

Price: US\$ 2,750.00 (Single User License)

ID: GC80C84A0B7EN

## Abstracts

Global Oncology Drugs Market – Drivers, Restraints, Opportunities, Trends, and Forecasts: 2018–2024

Overview: Oncology drugs or anti-cancer drugs or anti-neoplastic drugs are agents that can be used alone or in combination to control or destroy neoplastic cells. These agents can be either systemic or targeted. In systemic, the drug spreads throughout the body, whereas in targeted, the drug or substance identifies the specific location causing less harm to the growth of neighboring healthy cells. The oncology drugs market, by applications, is segmented into breast cancer, blood cancer, prostate cancer, gastrointestinal cancer, lung cancer, and others. The incidence of cancer is one of the leading causes of death globally due to unhealthy food habits, changing lifestyle, and increasing consumption of tobacco-related products. According to the estimation of the National Cancer Institute, in the US, around 1.6 million new cases of cancer were diagnosed and 595,690 people died due to cancer in 2016. Nearly 60% of new cancer cases are from Africa, Asia, Central and South American countries and almost 70% of cancer deaths are from these regions. The Indian Council for Medical Research estimated around 1.4 million new cancer cases in 2016, which is expected to rise to 1.7 million cases by 2020.

Increased prevalence of cancer, unhealthy lifestyle, and increasing geriatric population are the primary factors driving the market growth. However, the high cost of the drug & development process and side effects of the drug are the factors hampering the market growth. The development of pipeline oncology products and expiry of key patents are providing an opportunity for the manufacturers of cancer drugs.

Market Analysis: The global oncology drugs market is estimated to witness a CAGR of 7.0% during the forecast period 2018–2024. The market is analyzed based on three segments: therapeutic modality, applications, and regions.

**Regional Analysis:** The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (RoW). North America is set to be the leading region for the oncology drugs market growth followed by Europe, Asia Pacific, and Rest of the World.

**Therapeutic Modality Analysis:** The global oncology drugs market by therapeutic modality is segmented into chemotherapy, immunotherapy, targeted therapy, and others. Chemotherapy occupied the largest share in 2017, and immunotherapy is expected to grow at a high CAGR in the coming years due to high efficiency, increased preference of targeted immunotherapy from chemotherapy, and fewer side effects.

**Applications Analysis:** The global oncology drugs market by applications is segmented into breast cancer, blood cancer, prostate cancer, gastrointestinal cancer, lung cancer, and others. Blood cancer occupied the largest share in 2017, and lung cancer application is expected to be the fastest growing segment during the forecast period due to the high incidence of lung cancer and promising pipeline for NSCLC drugs.

**Key Players:** F. Hoffmann-La Roche Ltd., Bristol–Myers Squibb, Novartis AG, Johnson & Johnson, Pfizer, Inc., Celgene Corporation, AstraZeneca PLC, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Merck & Co., AbbVie, Inc., Sanofi, and other predominate & niche players.

**Competitive Analysis:** The high adoption of personalized medicine and immuno-oncology have fueled a shift in cancer treatment from chemotherapy in the past decade. During 2011–2017, around 84 new drugs have been approved across 22 indications globally, of which immuno-oncology PD-1 and PD-L1 inhibitors have seen a speedy uptake based on their notable clinical profile and approval for various cancers. Additionally, there is a robust late-stage oncology pipeline with around 630 unique molecules in the development, i.e., more than 7% when compared to the previous year, including 278 biological therapies and 82 vaccines. The market is dominated by key vendors such as F. Hoffmann-La Roche Ltd., Bristol–Myers Squibb, Novartis AG, Celgene Corporation, Pfizer Inc., and Johnson & Johnson; and products of these firms are available globally through their distributors and subsidiaries.

**Benefits:** The report provides complete details about the usage and adoption of oncology drugs in various applications and regions. With that, key stakeholders can know about the major trends, drivers, investments, vertical player's initiatives, government initiatives toward the product adoption in the upcoming years along with the

details of commercial products available in the market. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in specific verticals to analyze before investing or expanding the business in this market.

Key Stakeholders:

## Contents

### **1 INDUSTRY OUTLOOK**

- 1.1 Industry overview
- 1.2 Industry Trends
- 1.3 Total addressable market
- 1.4 Trends of cancer therapy market

### **2 REPORT OUTLINE**

- 2.1 Report Scope
- 2.2 Report Summary
- 2.3 Research Methodology
- 2.4 Report Assumptions

### **3 MARKET SNAPSHOT**

- 3.1 Market Definition – Infoholic Research
- 3.2 Segmented Addressable Market (SAM)
- 3.3 Trends of the oncology drugs market
- 3.4 Related Markets
  - 3.4.1 Over the counter drugs (OTC)
  - 3.4.2 Active pharmaceutical ingredients (APIs)
  - 3.4.3 Diabetes Drugs

### **4 MARKET OUTLOOK**

- 4.1 Oncology Drugs Approved by FDA (2014 – 2018)
- 4.2 Market segmentation
- 4.3 PEST Analysis
- 4.4 Porter 5(Five) Forces

### **5 MARKET CHARACTERISTICS**

- 5.1 DRO – Global Oncology Drugs Market Dynamics
  - 5.1.1 Drivers
    - 5.1.1.1 Increasing incidence of cancer across the globe
    - 5.1.1.2 Growing geriatric population

- 5.1.1.3 Expiration of patents
- 5.1.2 Opportunities
  - 5.1.2.1 Growing focus on personalized medicine
  - 5.1.2.2 Increasing healthcare spending
- 5.1.3 Restraints
  - 5.1.3.1 High cost of the drug
  - 5.1.3.2 Side effects of oncology drugs

## **6 THERAPEUTIC MODALITY: MARKET SIZE AND ANALYSIS**

- 6.1 Overview
- 6.2 Chemotherapy
- 6.3 Targeted therapy
- 6.4 Immunotherapy
- 6.5 Others

## **7 APPLICATION: MARKET SIZE AND ANALYSIS**

- 7.1 Overview
- 7.2 Blood cancer
- 7.3 Breast cancer
- 7.4 Gastro intestinal cancer
- 7.5 Lung cancer
- 7.6 Prostate cancer
- 7.7 Others

## **8 REGIONS: MARKET SIZE AND ANALYSIS**

- 8.1 Overview
- 8.2 North America
  - 8.2.1 Overview
  - 8.2.2 US
  - 8.2.3 Canada
- 8.3 Europe
  - 8.3.1 Overview
  - 8.3.2 UK
  - 8.3.3 Germany
  - 8.3.4 France
  - 8.3.5 Italy

## 8.4 APAC

### 8.4.1 Overview

### 8.4.2 India

### 8.4.3 China

## 8.5 Rest of the World

# 9 COMPETITIVE LANDSCAPE

## 9.1 Overview

# 10 VENDOR PROFILES

## 10.1 F.Hoffmann-La Roche Ltd

### 10.1.1 Overview

### 10.1.2 Business Unit

### 10.1.3 Geographic Presence

### 10.1.4

### 10.1.5 Business Focus

### 10.1.6 SWOT Analysis

### 10.1.7 Business Strategy

## 10.2 Novartis AG

### 10.2.1 Overview

### 10.2.2 Business Unit

### 10.2.3 Geographic Presence

### 10.2.4 Business Focus

### 10.2.5 SWOT Analysis

### 10.2.6 Business Strategy

## 10.3 Bristol-Myers Squibb

### 10.3.1 Overview

### 10.3.2 Geographic Presence

### 10.3.3 Business Focus

### 10.3.4 SWOT Analysis

### 10.3.5 Business Strategy

## 10.4 Celgene Corporation

### 10.4.1 Overview

### 10.4.2 Geographic Presence

### 10.4.3 Business Focus

### 10.4.4 SWOT Analysis

### 10.4.5 Business Strategy

## 10.5 Johnson & Johnson

### 10.5.1 Overview

### 10.5.2 Business Units

### 10.5.3 Geographic Revenue

### 10.5.4 Business Focus

### 10.5.5 SWOT Analysis

### 10.5.6 Business Strategies

## 10.6 Pfizer Inc.,

### 10.6.1 Overview

### 10.6.2 Geographic Presence

### 10.6.3 Business Focus

### 10.6.4 SWOT Analysis

### 10.6.5 Business Strategies

## 11 COMPANIES TO WATCH FOR

### 11.1 Astra Zenca PLC

#### 11.1.1 Overview

### 11.2 Eli Lilly and Company.

#### 11.2.1 Overview

### 11.3 GlaxoSmithKline plc

#### 11.3.1 Overview

### 11.4 Merck & Co.

#### 11.4.1 Overview

### 11.5 Sanofi

#### 11.5.1 Overview

### 11.6 Amgen Inc.

#### 11.6.1 Overview

### 11.7 AbbVie, Inc.

#### 11.7.1 Overview

## 12 ANNEXURE

### 12.1 Abbreviations

#### Tables

Table 1 GLOBAL ONCOLOGY DRUGS MARKET REVENUE BY REGIONS,  
2017–2024 (\$BILLION)

Table 1 GLOBAL ONCOLOGY DRUGS MARKET BY VENDOR RANKING, 2017

Table 2 OTHER PROMINENT VENDORS OF ONCOLOGY DRUGS MARKET

Table 3 F. HOFFMANN-LA ROCHE: OFFERINGS

Table 4 F. HOFFMANN-LA ROCHE: RECENT DEVELOPMENTS

Table 5 NOVARTIS AG: OFFERINGS

Table 6 NOVARTIS AG: RECENT DEVELOPMENTS

Table 7 BRISTOL-MYERS SQUIBB: OFFERINGS

Table 8 BRISTOL-MYERS SQUIBB: RECENT DEVELOPMENT

Table 9 CELGENE CORPORATION: OFFERINGS

Table 10 CELGENE CORPORATION: RECENT DEVELOPMENTS

Table 11 JOHNSON & JOHNSON: PRODUCT OFFERINGS

Table 12 JOHNSON & JOHNSON: RECENT DEVELOPMENTS

Table 13 PFIZER, INC.: PRODUCT OFFERINGS

Table 14 PFIZER INC.: RECENT DEVELOPMENTS

Table 15 ASTRA ZENECA PLC.: SNAPSHOT

Table 16 ASTRA ZENECA PLC: RECENT DEVELOPMENTS

Table 17 ELI LILLY AND COMPANY: SNAPSHOT

Table 18 ELI LILLY AND COMPANY: RECENT DEVELOPMENTS

Table 19 GLAXOSMITHKLINE PLC.: OVERVIEW

Table 20 GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS

Table 21 MERCK & CO: OVERVIEW

Table 22 MERCK & CO: RECENT DEVELOPMENTS

Table 23 SANOFI: SNAPSHOT

Table 24 SANOFI: RECENT DEVELOPMENTS

Table 25 AMGEN INC.: SNAPSHOT

Table 26 AMGEN INC: RECENT DEVELOPMENTS

Table 27 ABBVIE INC: SNAPSHOT

Table 28 ABBVIE INC: RECENT DEVELOPMENTS

## Charts

Chart 1 RESEARCH METHODOLOGY OF GLOBAL ONCOLOGY DRUGS MARKET

Chart 2 GLOBAL ONCOLOGY DRUGS MARKET REVENUE, 2017–2024 (\$BILLION)

Chart 3 NUMBER OF ONCOLOGY DRUGS APPROVED FROM 2014-2017

Chart 4 SEGMENTATION OF GLOBAL ONCOLOGY DRUGS MARKET

Chart 5 PEST ANALYSIS OF GLOBAL ONCOLOGY DRUGS MARKET

Chart 6 PORTER 5 FORCES ON GLOBAL ONCOLOGY DRUGS MARKET

Chart 7 DRO – IMPACT ANALYSIS OF GLOBAL ONCOLOGY DRUGS MARKET

Chart 8 KEY STAKEHOLDERS

Chart 9 GLOBAL ONCOLOGY DRUGS MARKET BY THERAPEUTIC MODALITY  
SEGMENTATION, 2017 (%)



Chart 10 GLOBAL ONCOLOGY DRUGS MARKET BY THERAPEUTIC MODALITY SEGMENTATION, 2024 (%)

Chart 11 GLOBAL CHEMOTHERAPY MARKET FORECAST, 2017–2024 (\$BILLION)

Chart 12 GLOBAL TARGETED THERAPY MARKET FORECAST, 2017–2024 (\$BILLION)

Chart 13 GLOBAL IMMUNOTHERAPY MARKET FORECAST, 2017–2024 (\$BILLION)

Chart 14 GLOBAL OTHERS MARKET FORECAST, 2017–2024 (\$BILLION)

Chart 15 GLOBAL ONCOLOGY DRUGS MARKET BY APPLICATION SEGMENTATION, 2017 (%)

Chart 16 GLOBAL ONCOLOGY DRUGS MARKET BY GEOGRAPHICAL SEGMENTATION, 2017 (%)

Chart 17 ONCOLOGY DRUGS MARKET REVENUE IN NORTH AMERICA, 2017–2024 (\$BILLION)

Chart 18 ONCOLOGY DRUGS MARKET REVENUE IN EUROPE, 2017–2024 (\$BILLION)

Chart 19 ONCOLOGY DRUGS REVENUE IN ASIA-PACIFIC, 2017–2024 (\$BILLION)

Chart 20 ONCOLOGY DRUGS MARKET REVENUE IN REST OF THE WORLD, 2017–2024 (\$BILLION)

Chart 25 NOVARTIS AG: OVERVIEW SNAPSHOT

Chart 26 NOVARTIS AG: BUSINESS UNITS

Chart 27 NOVARTIS AG: GEOGRAPHICAL PRESENCE

Chart 28 NOVARTIS AG: SWOT ANALYSIS

Chart 29 BRISTOL-MYERS SQUIBB.: OVERVIEW SNAPSHOT

Chart 30 BRISTOL-MYERS SQUIBB.: BUSINESS SEGMENTS

Chart 31 BRISTOL-MYERS SQUIBB.: GEOGRAPHIC PRESENCE

Chart 32 BRISTOL-MYERS SQUIBB.: SWOT ANALYSIS

Chart 33 CELGENE CORPORATION: OVERVIEW SNAPSHOT

Chart 34 CELGENE CORPORATION: GEOGRAPHIC PRESENCE

Chart 35 CELGENE CORPORATION: SWOT ANALYSIS

Chart 36 JOHNSON & JOHNSON: OVERVIEW SNAPSHOT

Chart 37 JOHNSON & JOHNSON: BUSINESS UNITS

Chart 38 JOHNSON & JOHNSON: GEOGRAPHIC REVENUE

Chart 39 JOHNSON & JOHNSON: SWOT ANALYSIS

Chart 40 PFIZER INC.: OVERVIEW SNAPSHOT

Chart 41 PFIZER INC.: BUSINESS UNITS REVENUE

Chart 42 PFIZER INC.: GEOGRAPHICAL PRESENCE

Chart 43 PFIZER INC.: SWOT ANALYSIS

## I would like to order

Product name: Global Oncology Drugs Market 2018-2024

Product link: <https://marketpublishers.com/r/GC80C84A0B7EN.html>

Price: US\$ 2,750.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GC80C84A0B7EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970